

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com **https:**//www.wjgnet.com

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number (Without Figures):_	Rate: 6.2 CNY per page
	Editing Fee: 99.2 CNY
Figure count: 4 Figure handling time	e: 0 min Rate: 1 CNY per min
	Editing Fee: <u>0 CNY</u>
XML and PDF converting time	e: 0 min Rate: 1 CNY per min
	Editing Fee: 0 CNY
Ma	nuscript word count: 3425
	Total Editing Fee: 99.2 CNY
	Scientific Editor: <u>Jia-Ping Yan</u>
Date of signature:4/6	/2023 (month/day/year)

		Comment
Item No.	Specific items for verification	s
item No.		Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Clinical Cases	
	Manuscript NO.: 82385	
	Column: Case Report	
1	Title: Late-onset MELAS syndrome with mitochondrial DNA	F2/1
1	3243A>G mutation masquerading as autoimmune encephalitis: A case	[Y]
	report	
	Authors: Jian-Wei Wang, Xiao-Bo Yuan and Hong-Fang Chen	
	Reviewer code: 03604107, 06495587, and 00741994	
	First decision: 2023-01-30 08:37	



2

Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Editorial Office's Comments

Editor: Science

The manuscript has been peer-reviewed, and it's ready for the first de cision.

Company Editor-in-Chief: I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1 Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and

[Y]



	confirm whether the figures are original (i.e. generated de novo by the	
	author(s) for this paper). If the picture is 'original', the author needs to	
	add the following copyright information to the bottom right-hand side	
	of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2023.	
	Before final acceptance, when revising the manuscript, the author	
	must supplement and improve the highlights of the latest cutting-edge	
	research results, thereby further improving the content of the	
	manuscript. To this end, authors are advised to apply a new tool, the	
	RCA. RCA is an artificial intelligence technology-based open	
	multidisciplinary citation analysis database. In it, upon obtaining	
	search results from the keywords entered by the author, "Impact Index	
	Per Article" under "Ranked by" should be selected to find the latest	
	highlight articles, which can then be used to further improve an article	
	under preparation/peer-review/revision. Please visit our RCA	
	database for more information at:	
	https://www.referencecitationanalysis.com/.	
3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is not	
	too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	[Y]
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first names	
6	are listed on the title page and are consistent with those listed in the	[Y]
	signed BPG Copyright License Agreement form.	



7	The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents and analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the manuscript. All authors have read and approve the final manuscript."	[Y]
8	The 'Supported by' statement describes the source(s) of financial support and includes the corresponding identification number(s) and program ID(s) if available, and contains no spelling errors.	[Y]
9	The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title (e.g., MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors.	[Y]
10	The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.	[Y]
11	The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words.	[Y]



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26 words).	
(no less than 120 words); and CONCLUSION (no more than 26	
words).	
The 'Key words' list provides 5-10 keywords that reflect the main	
content of the study. The first letter of each keyword is capitalized,	[Y]
and each keyword is separated by a semicolon.	
The "citation" contains authors' names and manuscript title. The name	
of the first author should be typed in bold letters; the family (sur)	
name of all authors should be typed with the first letter capitalized,	
followed by their abbreviated first and middle initials. For example,	F 2 / 3
an article by Jae Moon Yoon, Ki Young Son, Chun Sick Eom, Daniel	[Y]
Durrance, Sang Min Park will be written as Yoon JM, Son KY, Eom CS,	
Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk	
of gastric cancer: A meta-analysis. World J Gastroenterol 2019; In press	
The 'Core tip' provides a summary (less than 100 words) of the study	
that outlines the most innovative and important arguments and core	[Y]
contents of the paper and will serve to effectively attract readers.	
The 'INTRODUCTION' section clearly describes the relevant	
background information for the study. Only the most relevant and	
current (within the past 5 years) literature is cited, with the exception	
of rare instances of seminal literature citations. All technical terms	[Y]
and/or abbreviations are explained and/or defined, with the full	
name of abbreviations given upon first appearance in the text and the	
abbreviation presented in parentheses [i.e., "computed tomography	
(CT)"]. First-person pronouns (e.g., 'I', 'we') are used appropriately to	
clearly indicate the work performed by the author(s). When	
weaknesses of previous studies are described in the text to highlight	
the innovations related to the current study, the information is	
presented carefully.	



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

https://www.wjgnet.com

E-mail: bpgoffice@wjgnet.com

	The 'MATERIALS AND METHODS' section clearly and accurately	
16	describes all materials and methods used to obtain the data presented	[N]
	in the article and is adequate for a reader to repeat the study.	
	The 'RESULTS' section concisely describes the observational and	
	experimental results. Representative data and data that have scientific	
	significance are emphasized. Data is presented in either the text, a	
17	table or figure (i.e., chart, diagram, graph or image), but is not	[N]
	repeated among each. Information presented in the tables and figures	
	clearly describes the trends, meaning, and inferences. Results	
	described in textual form are accurate, concise and clear.	
	Statistical symbols are accurate. Statistical significance is expressed as	
	$^{\mathrm{a}}P$ < 0.05, $^{\mathrm{b}}P$ < 0.01 (P > 0.05 usually does not need to be denoted). If	
18	there are other series of P values, ^{c}P < 0.05 and ^{d}P < 0.01 are used, and	[N]
	a third series of P values is expressed as $^{\rm e}P$ < 0.05 and $^{\rm f}P$ < 0.01.	
	Statistical data is expressed as mean ± SD or mean ± SE.	
	The 'DISCUSSION' section (1) describes the main purpose and	
	hypothesis of the study; (2) summarizes the most important results; (3)	
	illustrates and explains the results (but does not simply repeat the	
19	data) and draws conclusions or inferences based on the results; (4)	[V]
19	points out the limitations of the study and their impact on the results,	[Y]
	as well as proposes further advice on future research topic(s) or	
	direction(s); and (5) describes the theoretical significance and practical	
	value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	
20	individuals or organizations for technical support (i.e., providing	
	instrumentation, equipment or experimental materials, and/or	[N]
	assistance in experimental work), non-technical services (i.e., useful	[+ N]
	inspiration, suggestions, guidance, or review), and/or any other	
	auxiliary work.	
21	The 'ARTICLE HIGHLIGHTS' section provides comments for original	[N]



	articles in accordance with the specified format.	
	The /DEEDENICEC/ and then the reference in the Warren	
	The 'REFERENCES' section lists the references in the Vancouver style.	
	This style uses Arabic numeral in-text citations based on the order of	
	the first appearance of a source in the text. For citations where the	
	author's name is indicated in the text, a superscript number should be	
	placed following the name (i.e., "Pang et al"). For citations where no	
22	author is indicated, a superscript number should be placed at the end	[Y]
	of the sentence. Respective examples are: "Ma ^[1] reported", "Pan et	
	al ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript	
	numbers are used when the reference number is described in the text;	
	for example, "The experimental method used has been described in	
	reference [8]." The style of reference citations in tables is the same as	
	that in the text (e.g., Pan et al ^[2-5] , please see reference [8]).	
	Journal references have been verified to ensure that there are no	
	duplicate references and that the PMID numbers are correct. For	[Y]
	references not yet included in PubMed: the name of Chinese journals	
23	is spelled out using Chinese Pinyin, with the first letter of each word	
23	capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of journals in	
	other languages are listed according to indexing information retrieved	
	from Google. Book references are presented with all the information	
	relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as	
	follows:	52/3
	<u>Commentary:</u> no less than 50;	
24	Review: no less than 100;	[Y]
	Article: no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the	
25	manuscript type (e.g., Manuscript NoInstitutional review board	[N]
	statement, Manuscript NoAnimal care and use statement, etc.).	
-		



The names of the peer reviewers and the scientific editor are present at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang JL). The order and numerical labeling of tables and figures is consistent with their appearance and presentation in the text. Symbols in tables (e.g., +, -, -, *, +, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript NoReview; e.g., 870-Review). The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial			
the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang JL). The order and numerical labeling of tables and figures is consistent with their appearance and presentation in the text. Symbols in tables (e.g., +, -, ×, *, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	26	The names of the peer reviewers and the scientific editor are present at	[]]
with their appearance and presentation in the text. Symbols in tables (e.g., +, -, ×, +, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: 28		the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang JL).	[+]
(e.g., +, -, ×, +, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		The order and numerical labeling of tables and figures is consistent	
footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		with their appearance and presentation in the text. Symbols in tables	
consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		(e.g., +, -, \times , \div , *) correctly correspond to the definitions in the	
consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	27	footnotes. Only one legend is provided for each multi-panel figure	[V]
changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	27	consisting of color graphs, black and white graphs, or line graphs that	[1]
B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		depicts data of the same theme. For example: Figure 1 Pathological	
Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. 29 The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. 30 The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		changes in atrophic gastritis tissue before and after treatment. A:;	
including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		B:; C:; D:; E:; F:	
amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		Split pictures include flow charts, line graphs, histograms, and graphs	F2/2
The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	28	including text. Unsplit pictures include meta-analysis diagrams, PCR	[Y]
according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		amplification curves, and survival curves.	
according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	20	The author(s) highlighted the changes made to the manuscript	[]/[]
changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	29	according to the peer-reviewers' comments.	[Y]
changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	20	The responses to the peer-reviewers' comments are consistent with the	F2/1
NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	30	changes made to the manuscript.	[1]
The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		The revised manuscript is provided (file name: Manuscript	
Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		NoReview; <i>e.g.</i> , 870- Review).	
Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	21	The letter of peer-reviewers' comments is provided (file name:	[Y]
reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	31	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	
The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		The response letter is provided (file name: Manuscript NoAnswering	
Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		reviewers; e.g., 870-Answering reviewers).	
approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		The related ethics and relevant documents are provided, such as (1)	
form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	32	Approved grant application form(s) or funding agency copy of any	
NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		approval document(s) (file name: Manuscript NoGrant application	
name: Manuscript NoConflict-of-interest statement); (4) Clinical trial		form(s)); (2) Biostatistics review certificate (file name: Manuscript	[Y]
		NoBiostatistics statement); (3) Conflict-of-interest statement (file	
registration statement (file name: Manuscript NoClinical trial		name: Manuscript NoConflict-of-interest statement); (4) Clinical trial	
		registration statement (file name: Manuscript NoClinical trial	



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

l ·	
registration statement); (5) Institutional review board approval form	
or document (file name: Manuscript NoInstitutional review board	
statement); (6) Institutional animal care and use committee approval	
form or document (file name: Manuscript NoInstitutional animal	
care and use committee statement), and (7) Signed informed consent	
form(s) or document(s) (file name: Manuscript NoInformed consent	
statement).	
All authors signed the BPG Copyright license agreement form (file	
name: Manuscript NoCopyright license agreement; <i>e.g.</i> ,	[Y]
870-Copyright license agreement).	
The language certificate provided by authors who are non-native	
speakers of English meets the BPG requirements (file name:	[Y]
Manuscript NoLanguage certificate; e.g., 870-Language certificate).	
The photos licensed in the Agreement for Use of Personal Photos are	
consistent with those in the paper (file name: Manuscript	[N]
NoAgreement for use of personal photos; e.g., 870-Agreement for use	
of personal photos).	
This document (Checklist of Responsibilities for Scientific Editors) has	
been saved under the file name: manuscript NoScientific editor work	[Y]
list (e.g., 870-Scientific editor work list).	
A CrossCheck investigation (an effective tool for detecting unoriginal	
content, enabling our editors to preserve the journal's integrity and the	
authors' copyright) has been performed for the manuscript via the	
website: http://www.ithenticate.com/. The results document	
contains the following information for the manuscript: "Name of	[Y]
journal", "Manuscript No.", "Columns", "Title" and "Author list".	
The Figure of the CrossCheck results is saved in JPEG format (.jpg) at	
1440×680 pixel resolution. The PDF of the <i>CrossCheck</i> results has been	
saved under the file name: manuscript No CrossCheck report (e.g.,	
870-CrossCheck report). The Google searches have also been	



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

	performed to further ensure publication of original content.
38	The text of the manuscript is typed in Book Antiqua font, 12 pt, with 1.5 line spacing.
Responsibiliti es of scientific editors	The primary responsibilities of our scientific editors include carefully checking the entire manuscript and all accompanying materials for: (1) errors in spelling, grammar, punctuation and wording; (2) suitability of tables, figures, figure data and legends; (3) accurate and appropriate presentation of symbols ($e.g. +, -, \times, \div, \%, *$) in tables and figures; and (4) complete and comprehensive revision of the manuscript according to the reviewers' comments.
Publication process	Manuscript reception and registration→Initial review by scientific editor→Peer review→End of peer review→First round of meeting evaluation→To be accepted→Revision by the author(s)→Second round of meeting evaluation→To be accepted/revised/rejected→Final review by the Editor-in-Chief (final quality control for academic content and language quality)→Final acceptance and charging of publication fee→Language editing→Production→Proofreading by scientific editor→Proofreading by deputy editor→Final review by Editor-in-Chief→Release of online open-access papers in electronic form on the BPG website→Release of online papers on PubMed Central→Delivery of high-quality PDF reprints to the author(s)→End of the publication process.